Safety Study of DuoTrav APS in Patients With Open-Angle Glaucoma or Ocular Hypertension

Alcon Research155 enrolled

Overview

The purpose of this study is to describe the long-term safety of a fixed combination product containing an alternative preservative, dosed once daily for 12 months, in patients with open-angle glaucoma or ocular hypertension.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

155

Conditions

Open-angle Glaucoma Ocular Hypertension

Interventions

Travoprost/Timolol Maleate Fixed Combination solutionDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Willing and able to sign an informed consent document. * Open-angle glaucoma or ocular hypertension who would benefit from a fixed combination medication, in the opinion of the investigator. * Stable treatment of an IOP-lowering medication. * Other protocol-defined inclusion criteria may apply. Exclusion Criteria: * Pregnant, breastfeeding, or not using adequate birth control. * Best-corrected visual acuity (BCVA) worse than 55 ETDRS letters. * Other protocol-defined exclusion criteria may apply.

Outcomes

Primary Outcomes

Adverse Events (AEs)

Time frame: 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.